The Latest Cardiac and Vascular News
HOUSTON, May 12, 2022 /PRNewswire/ — Tim Daugherty, CEO of Millar, Inc., a medical device manufacturer and OEM pressure-sensor solutions provider, is honored to be named one of The Top 50 Healthcare Technology CEOs of 2022, published by the Healthcare Technology Report. Now more than ever, the importance of the healthcare technology field is […]
Financing To Support Commercial Acceleration of the Optimizer Smart Mini, Enrollment in the Landmark AIM HIGHer Clinical Trial, and Continued Development of a CCM-D Combination MARLTON, N.J., May 12, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure […]
SUNNYVALE, Calif., May 11, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter of 2022 and filed its quarterly report on Form 10-Q for the three months ended March 31, […]
– Secured access to new capital through debt and equity transactions – Increased utilization of Treprostinil Injection with increasing payer generic mandates – Advanced Hatch-Waxman litigation in support of final regulatory approval of YUTREPIA™ (treprostinil) inhalation powder – Company to host webcast and conference call today at 8:30 a.m. ET […]
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM ongoing LianBio’s partner, Tarsus, announced positive topline data from the Phase 3 Saturn-2 clinical trial […]
TN-201 Received Orphan Medicinal Product Designation from the European Commission Preclinical TN-401 Data Presented at Heart Rhythm 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today […]
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on […]
Increased commercial momentum and great interest in CADScor® System on the US market 2022 has started off positiv with important steps on the US market, recruitment of key staff and continued validation that our business model works. We report doubled sales of patches compared with the corresponding quarter of 2021. […]
SPARKS, Md., May 10, 2022 (GLOBE NEWSWIRE) — TridentCare, a national leader of portable diagnostic services, announces its new partnership with Harness Health Partners to provide mobile X-ray, Ultrasound and EKG services across the United States. “This is an exciting time for TridentCare,” says TridentCare CEO David Velez. “We are excited […]
Westport, CT, May 11, 2022 (GLOBE NEWSWIRE) — To date, Company’s FDA 510(k) cleared PURE EP(TM) system has completed over 2,200 patient cases with 75 physicians at 17 hospitals across the United States The Company adds new executives to accelerate sustained commercial momentum developing a national installed base of the PURE EP […]
